Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Legend Biotech downgraded to Equal Weight from Overweight at Morgan Stanley » 07:33
01/06/22
01/06
07:33
01/06/22
07:33
LEGN

Legend Biotech

$44.59 /

-2.175 (-4.65%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison downgraded Legend Biotech to Equal Weight from Overweight with an unchanged price target of $51. He continues to view Legend as "a compelling cell therapy platform company" and still forecasts a strong multiple myeloma launch from Cilta-cel in 2022. Despite his confidence in the launch, Harrison believes expectations are high and reflected in the stock, he tells investors.

ShowHide Related Items >><<
LEGN Legend Biotech
$44.59 /

-2.175 (-4.65%)

LEGN Legend Biotech
$44.59 /

-2.175 (-4.65%)

01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21
Fly Intel: Top five analyst initiations
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
LEGN Legend Biotech
$44.59 /

-2.175 (-4.65%)

  • 16
    Dec
LEGN Legend Biotech
$44.59 /

-2.175 (-4.65%)

Recommendations
Legend Biotech named a top pick for 2022 at Piper Sandler » 04:54
01/03/22
01/03
04:54
01/03/22
04:54
LEGN

Legend Biotech

$46.62 /

-3.1 (-6.23%)

, BMY

Bristol-Myers

$62.36 /

-0.15 (-0.24%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff named Legend Biotech (LEGN) a top pick for 2022 and keeps an Overweight rating on the shares with a $66 price target. The analyst is confident in an FDA approval of the company's autologous BCMA CAR-T cilta-cel in late-line multiple myeloma by the February 28 action date date based on positive Phase Ib/II CARTITUDE-1 data. Based on these "unprecedented" results, cilta-cel has "best-in-class potential" over Bristol-Myer's (BMY) Abecma, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
LEGN Legend Biotech
$46.62 /

-3.1 (-6.23%)

BMY Bristol-Myers
$62.36 /

-0.15 (-0.24%)

LEGN Legend Biotech
$46.62 /

-3.1 (-6.23%)

12/21/21
Fly Intel: Top five analyst initiations
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
BMY Bristol-Myers
$62.36 /

-0.15 (-0.24%)

12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/20/21 JPMorgan
Bristol-Myers shares should rebound into 2022, says JPMorgan
12/17/21 Goldman Sachs
Goldman starts Bristol-Myers with Buy, sees 16% share upside
LEGN Legend Biotech
$46.62 /

-3.1 (-6.23%)

BMY Bristol-Myers
$62.36 /

-0.15 (-0.24%)

  • 16
    Dec
BMY Bristol-Myers
$62.36 /

-0.15 (-0.24%)

LEGN Legend Biotech
$46.62 /

-3.1 (-6.23%)

BMY Bristol-Myers
$62.36 /

-0.15 (-0.24%)

BMY Bristol-Myers
$62.36 /

-0.15 (-0.24%)

Hot Stocks
Legend Biotech appoints CEO and CFO Ying Huang to Board » 08:34
12/30/21
12/30
08:34
12/30/21
08:34
LEGN

Legend Biotech

$47.39 /

-0.94 (-1.94%)

Legend Biotech has…

Legend Biotech has appointed CEO and CFO Ying Huang as a director to Legend's Board of Directors. Huang will serve as a Class I director. Ying Huang has served as CEO since September 2020 and as CFO since July 2019. Prior to joining Legend Biotech, Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities from August 2014 to July 2019.

ShowHide Related Items >><<
LEGN Legend Biotech
$47.39 /

-0.94 (-1.94%)

LEGN Legend Biotech
$47.39 /

-0.94 (-1.94%)

12/21/21
Fly Intel: Top five analyst initiations
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
LEGN Legend Biotech
$47.39 /

-0.94 (-1.94%)

  • 16
    Dec
LEGN Legend Biotech
$47.39 /

-0.94 (-1.94%)

Initiation
Fly Intel: Top five analyst initiations » 10:03
12/21/21
12/21
10:03
12/21/21
10:03
LEGN

Legend Biotech

$48.09 /

+0.98 (+2.08%)

, BOOT

Boot Barn

$108.88 /

+3.59 (+3.41%)

, TARS

Tarsus Pharmaceuticals

$24.87 /

+1.08 (+4.54%)

, APG

APi Group

$23.85 /

+0.68 (+2.93%)

, GDRX

GoodRx

$34.79 /

+1.08 (+3.20%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Legend Biotech (LEGN) initiated with an Overweight at Piper Sandler. 2. Boot Barn (BOOT) initiated with a Buy at Benchmark. 3. Tarsus Pharmaceuticals (TARS) initiated with a Buy at H.C. Wainwright. 4. APi Group (APG) reinstated with a Buy at Citi. 5. GoodRx (GDRX) initiated with an Overweight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
TARS Tarsus Pharmaceuticals
$24.87 /

+1.08 (+4.54%)

LEGN Legend Biotech
$48.09 /

+0.98 (+2.08%)

GDRX GoodRx
$34.79 /

+1.08 (+3.20%)

BOOT Boot Barn
$108.88 /

+3.59 (+3.41%)

APG APi Group
$23.85 /

+0.68 (+2.93%)

LEGN Legend Biotech
$48.09 /

+0.98 (+2.08%)

12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
BOOT Boot Barn
$108.88 /

+3.59 (+3.41%)

12/21/21 Benchmark
Benchmark starts 'national leader' Boot Barn at Buy with $135 target
12/21/21 Benchmark
Boot Barn initiated with a Buy at Benchmark
11/30/21 Jefferies
Boot Barn assumed with a Buy at Jefferies
11/18/21 Cowen
Cowen lays out top retail picks into strongest holiday in 20 years
TARS Tarsus Pharmaceuticals
$24.87 /

+1.08 (+4.54%)

12/21/21 H.C. Wainwright
Tarsus Pharmaceuticals initiated with a Buy at H.C. Wainwright
11/22/21 Oppenheimer
Tarsus Pharmaceuticals initiated with an Outperform at Oppenheimer
10/07/21 Raymond James
Tarsus Pharmaceuticals price target raised to $65 from $50 at Raymond James
06/29/21 Raymond James
Tarsus Pharmaceuticals price target raised to $50 from $39 at Raymond James
APG APi Group
$23.85 /

+0.68 (+2.93%)

12/21/21 Citi
APi Group reinstated with a Buy at Citi
02/16/21 Citi
APi Group price target raised to $22 from $21 at Citi
GDRX GoodRx
$34.79 /

+1.08 (+3.20%)

12/21/21 Stephens
GoodRx initiated with an Overweight at Stephens
12/01/21 Jefferies
GoodRx initiated with a Buy at Jefferies
11/15/21 Deutsche Bank
GoodRx price target lowered to $44 from $47 at Deutsche Bank
11/11/21 SVB Leerink
GoodRx price target lowered to $49 from $56 at SVB Leerink
TARS Tarsus Pharmaceuticals
$24.87 /

+1.08 (+4.54%)

LEGN Legend Biotech
$48.09 /

+0.98 (+2.08%)

GDRX GoodRx
$34.79 /

+1.08 (+3.20%)

BOOT Boot Barn
$108.88 /

+3.59 (+3.41%)

APG APi Group
$23.85 /

+0.68 (+2.93%)

  • 16
    Dec
  • 15
    Sep
GDRX GoodRx
$34.79 /

+1.08 (+3.20%)

LEGN Legend Biotech
$48.09 /

+0.98 (+2.08%)

GDRX GoodRx
$34.79 /

+1.08 (+3.20%)

APG APi Group
$23.85 /

+0.68 (+2.93%)

GDRX GoodRx
$34.79 /

+1.08 (+3.20%)

BOOT Boot Barn
$108.88 /

+3.59 (+3.41%)

Initiation
Legend Biotech initiated with an Overweight at Piper Sandler » 04:54
12/21/21
12/21
04:54
12/21/21
04:54
LEGN

Legend Biotech

$47.11 /

+0.39 (+0.83%)

, BMY

Bristol-Myers

$61.69 /

+0.11 (+0.18%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff initiated coverage of Legend Biotech (LEGN) with an Overweight rating and $66 price target. The analyst is confident in FDA approval of the company's autologous BCMA CAR-T cilta-cel in late-line multiple myeloma. He believes cilta-cel has "best-in-class potential" over Bristol-Myer's (BMY) Abecma and notes that cilta-cel is partnered with Janssen in a 50/50 global profit share, except in China where Legend retains 70%. Legend is developing a "rich pipeline of autologous and differentiated allogeneic CellRx," contends Tenthoff.

ShowHide Related Items >><<
LEGN Legend Biotech
$47.11 /

+0.39 (+0.83%)

BMY Bristol-Myers
$61.69 /

+0.11 (+0.18%)

LEGN Legend Biotech
$47.11 /

+0.39 (+0.83%)

10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
BMY Bristol-Myers
$61.69 /

+0.11 (+0.18%)

12/20/21 JPMorgan
Bristol-Myers shares should rebound into 2022, says JPMorgan
12/17/21 Goldman Sachs
Goldman starts Bristol-Myers with Buy, sees 16% share upside
12/17/21 Goldman Sachs
Bristol-Myers initiated with a Buy at Goldman Sachs
12/14/21 SVB Leerink
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
LEGN Legend Biotech
$47.11 /

+0.39 (+0.83%)

BMY Bristol-Myers
$61.69 /

+0.11 (+0.18%)

  • 16
    Dec
BMY Bristol-Myers
$61.69 /

+0.11 (+0.18%)

LEGN Legend Biotech
$47.11 /

+0.39 (+0.83%)

BMY Bristol-Myers
$61.69 /

+0.11 (+0.18%)

BMY Bristol-Myers
$61.69 /

+0.11 (+0.18%)

Over a month ago
Syndicate
Legend Biotech 7.5M share Secondary priced at $40.00 » 08:35
12/16/21
12/16
08:35
12/16/21
08:35
LEGN

Legend Biotech

$41.18 /

-7.39 (-15.22%)

Morgan Stanley, JPMorgan,…

Morgan Stanley, JPMorgan, Jefferies, Piper Sandler and Barclays acted as joint book running managers for the offering.

ShowHide Related Items >><<
LEGN Legend Biotech
$41.18 /

-7.39 (-15.22%)

LEGN Legend Biotech
$41.18 /

-7.39 (-15.22%)

10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
LEGN Legend Biotech
$41.18 /

-7.39 (-15.22%)

  • 16
    Dec
LEGN Legend Biotech
$41.18 /

-7.39 (-15.22%)

Syndicate
Legend Biotech offers to sell $300M in in ADS » 16:28
12/14/21
12/14
16:28
12/14/21
16:28
LEGN

Legend Biotech

$48.59 /

-2.22 (-4.37%)

Morgan Stanley, J.P.…

Morgan Stanley, J.P. Morgan, Jefferies, Piper Sandler & Co. and Barclays are serving as joint book-running managers for the offering. BTIG is serving as a co-manager for the offering.

ShowHide Related Items >><<
LEGN Legend Biotech
$48.59 /

-2.22 (-4.37%)

LEGN Legend Biotech
$48.59 /

-2.22 (-4.37%)

10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
LEGN Legend Biotech
$48.59 /

-2.22 (-4.37%)

LEGN Legend Biotech
$48.59 /

-2.22 (-4.37%)

Hot Stocks
Legend shares new data on CARTITUDE clinical development program » 09:15
12/13/21
12/13
09:15
12/13/21
09:15
LEGN

Legend Biotech

$50.50 /

-0.775 (-1.51%)

Legend Biotech announced…

Legend Biotech announced new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel, cilta-cel, in the treatment of multiple myeloma, which were presented at the 63rd American Society of Hematology Cilta-cel is an investigational B-cell maturation antigen -directed chimeric antigen receptor T cell therapy being studied as a one-time treatment for multiple myeloma. The median time to first response was one month the median time to best response was 2.6 months ; and the median time to complete response or better was 2.9 months .1 The longer-term data showed no new safety signals and there were no new events of cilta-cel-related neurotoxicity or movement and neurocognitive treatment emergent adverse events reported since the median ~1 year follow-up. Implementation of MNT mitigation measures has decreased the incidence rate to 0.5 percent in the CARTITUDE clinical development program. In the 18-month follow-up data previously presented at ASCO 2021, the most common hematologic adverse events observed were neutropenia ; anemia ; thrombocytopenia ; leukopenia and lymphopenia (53 percent).2 At 18 months, cytokine release syndrome of any grade was observed in 95 percent of patients with a median duration of four days and median time to onset of seven days. Of the 92 patients with CRS, 95 percent experienced Grade 1/2 events and CRS resolved in 91 patients within 14 days of onset. Neurotoxicity of any grade was observed in 21 percent of patients, with Grade 3 or higher neurotoxicity observed in 10 percent of patients. "Patients with heavily pre-treated multiple myeloma often have exhausted available treatment options and face poor prognoses. The updated results from the CARTITUDE-1 trial continue to suggest that cilta-cel may provide this patient population with lasting deep and durable responses," said Thomas Martin, M.D., director of clinical research, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, interim Division Chief, co-director, Myeloma Program and co-leader, Hematopoietic Malignancies Program, at UCSF Helen Diller Family Comprehensive Cancer Center, and principal study investigator. "As a one-time infusion that shows potential to improve long-term survival and offer patients a break in ongoing treatments, cilta-cel may offer hope to patients, caregivers and physicians."

ShowHide Related Items >><<
LEGN Legend Biotech
$50.50 /

-0.775 (-1.51%)

LEGN Legend Biotech
$50.50 /

-0.775 (-1.51%)

10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
LEGN Legend Biotech
$50.50 /

-0.775 (-1.51%)

LEGN Legend Biotech
$50.50 /

-0.775 (-1.51%)

Hot Stocks
Legend Biotech reports Janssen summited NDA to Japan's MHLW for cilta-cel » 09:38
12/07/21
12/07
09:38
12/07/21
09:38
LEGN

Legend Biotech

$44.95 /

+0.7 (+1.58%)

, JNJ

Johnson & Johnson

$162.91 /

+3.555 (+2.23%)

Legend Biotech (LEGN)…

Legend Biotech (LEGN) announced the submission of a New Drug Application, or NDA, to the Japanese Ministry of Health, Labour and Welfare for ciltacabtagene autoleucel, or "cilta-cel," by its collaboration partner, Janssen Pharmaceutical K.K. (JNJ). Cilta-cel is an investigational B-cell maturation antigen-directed chimeric antigen receptor-T cell therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. "Today's submission is an encouraging step in our mission to provide a potentially transformative cell therapy option to patients with multiple myeloma. We look forward to closely collaborating with our partner Janssen and the MHLW in order to make cilta-cel available to patients living with relapsed or refractory multiple myeloma, who have exhausted several standard-of-care treatments and are facing poor prognoses," said Ying Huang, PhD, CEO and CFO of Legend Biotech.

ShowHide Related Items >><<
LEGN Legend Biotech
$44.95 /

+0.7 (+1.58%)

JNJ Johnson & Johnson
$162.91 /

+3.555 (+2.23%)

LEGN Legend Biotech
$44.95 /

+0.7 (+1.58%)

10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
JNJ Johnson & Johnson
$162.91 /

+3.555 (+2.23%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
LEGN Legend Biotech
$44.95 /

+0.7 (+1.58%)

JNJ Johnson & Johnson
$162.91 /

+3.555 (+2.23%)

JNJ Johnson & Johnson
$162.91 /

+3.555 (+2.23%)

LEGN Legend Biotech
$44.95 /

+0.7 (+1.58%)

JNJ Johnson & Johnson
$162.91 /

+3.555 (+2.23%)

JNJ Johnson & Johnson
$162.91 /

+3.555 (+2.23%)

Hot Stocks
Legend submits NDA to Japan regulator for BCMA CAR-T therapy Cilta-cel for RRMM » 08:41
12/06/21
12/06
08:41
12/06/21
08:41
LEGN

Legend Biotech

$44.36 /

-4.465 (-9.15%)

, JNJ

Johnson & Johnson

$159.37 /

+2.25 (+1.43%)

Legend Biotech (LEGN)…

Legend Biotech (LEGN) announces submission of a New Drug Application, NDA, to the Japanese Ministry of Health, Labour and Welfare, MHLW, for ciltacabtagene autoleucel by its collaboration partner, Janssen Pharmaceutical (JNJ) . Cilta-cel is an investigational B-cell maturation antigen -directed chimeric antigen receptor CAR-T cell therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor , an immunomodulatory agent , and an anti-CD38 antibody. The submission is based on results from the Phase 1b/2 CARTITUDE-1 study conducted in the US and Japan, which evaluated the efficacy and safety of cilta-cel for patients with relapsed or refractory multiple myeloma.1 Cilta-cel is currently under regulatory review by several health authorities around the world, including the United States and Europe. "Today's submission is an encouraging step in our mission to provide a potentially transformative cell therapy option to patients with multiple myeloma," said Ying Huang, PhD, CEO and CFO of Legend Biotech. "We look forward to closely collaborating with our partner Janssen and the MHLW in order to make cilta-cel available to patients living with relapsed or refractory multiple myeloma, who have exhausted several standard-of-care treatments and are facing poor prognoses."

ShowHide Related Items >><<
LEGN Legend Biotech
$44.36 /

-4.465 (-9.15%)

JNJ Johnson & Johnson
$159.37 /

+2.25 (+1.43%)

LEGN Legend Biotech
$44.36 /

-4.465 (-9.15%)

10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
05/17/21 BTIG
Legend Biotech initiated with a Buy at BTIG
JNJ Johnson & Johnson
$159.37 /

+2.25 (+1.43%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
LEGN Legend Biotech
$44.36 /

-4.465 (-9.15%)

JNJ Johnson & Johnson
$159.37 /

+2.25 (+1.43%)

JNJ Johnson & Johnson
$159.37 /

+2.25 (+1.43%)

LEGN Legend Biotech
$44.36 /

-4.465 (-9.15%)

JNJ Johnson & Johnson
$159.37 /

+2.25 (+1.43%)

JNJ Johnson & Johnson
$159.37 /

+2.25 (+1.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.